Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KLaSSEC: Ketamine + Levetiracetam for Pediatric Status Epilepticus
NCT07046611Phase 3Recruiting
- Sponsor
- Sohag University
- Start
- Jul 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Generalized Convulsive Status Epilepticus (GCSE) comparing Ketamine + Levetiracetam with Placebo + Levetiracetam (2 arms). Primary endpoint: Number of participants with cessation of seizures at 20-minute. Started Jul 2025; status: recruiting.
02
Drugs
ketamine
03
Conditions
Generalized Convulsive Status Epilepticus (GCSE)
Beyond the preview
Go deeper on NCT07046611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07046611.